Applying Biologic Therapies to the Management of Patients with Rheumatoid Arthritis

Program Overview

The challenge of providing uniformly effective rheumatoid arthritis care has thus far defied a simple solution. Variations in care range from the appropriate adjustment or switching of therapy subsequent to increased disease activity to the selection of therapeutic agent chosen following failure. This program is designed to improve the understanding of advances in immunopathologic discoveries which provide valuable aid in individualized treatment plans and the appropriate patient selection of available DMARDS and biologic therapeutics. Also, expert rheumatologists will discuss the latest data of head-to-head trials and recommendations for clinical effectiveness. This CME program will bring rheumatologists and other health care professionals up to date in managing their patients with rheumatoid arthritis.

Target Audience

This activity was designed to meet the needs of rheumatologists, immunologists, primary care practitioners and other healthcare professionals who care for patients with rheumatoid arthritis.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Explain the advances in immunopathologic discoveries in rheumatoid arthritis and how this is shaping the development of therapies
  2. Compare the benefits, risks, and modes of action of available DMARD and biologic therapeutics
  3. Analyze the latest data of head-to-head trials that provide information on clinical effectiveness
  4. Develop individualized management strategies for rheumatoid arthritis that utilizes guideline recommendations for diagnosis, treatment adjustments, and sequencing of agents complemented by clinical experience


Alan L. Epstein, MD, FACR, FACP
Associate Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
Joel M. Kremer, MD
Pfaff Family Professor of Medicine
Albany Medical College
Director of Research
The Center for Rheumatology
Albany, New York
Evan Siegel, MD
Arthritis and Rheumatism Associates
Rockville, Maryland

Disclosure Statements

It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With
Alan L. Epstein, MD, FACR, FACPSpeaker’s Bureau: Abbvie Inc.; Bristol-Myers Squibb; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer, Inc.
Joel M. Kremer, MDConsultant/Advisor:Abbvie Inc.; Amgen, Inc.; Bristol-Myers Squibb; Genentech, Inc.; Pfizer, Inc.
Grant/Research Support: Abbvie Inc.; Amgen, Inc.; Bristol-Myers Squibb; Genentech, Inc.; Pfizer, Inc.; UCB
Stock Ownership: Cognition Pharmaceuticals, Inc.
Speaker's Bureau: Abbvie Inc.; Pfizer, Inc.
Evan Siegel, MDConsultant/Advisor: Abbvie Inc.
Speaker's Bureau: Abbvie Inc.; Amgen, Inc.

Planners, Managers, Reviewers: Timothy Hayes, MD, PhD, Margaret Taylor, MEd, Esther Polgar, Kristen Scollon, Sandy Breslow, Jill McNair, and Tania Dickson, PhD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Peer Review

This enduring activity has been peer-reviewed by the Seminars in Arthritis and Rheumatism Journal.

Accreditation Statement

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Original Course Open: September 11, 2013

Course Expired: September 10, 2014




Financial Support

This activity has been supported by an independent educational grant from Bristol-Myers Squibb.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Bristol-Myers Squibb do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course details

  • Course opens: September 11, 2013
  • Course expires: September 10, 2016

Please log in or register to take this Course.